This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): KB2115
Description: Eprotirome works by selectively stimulating the thyroid hormone receptor which is the protein in the body that mediates the effects of thyroid hormone. Eprotirome has receptor and tissue selective properties and therefore negative effects on the heart that are the result of using natural thyroid hormone can be avoided.
Deal Structure: In April 2011, Karo Bio announced that the company and Alkem Laboratories entered into a collaboration and license agreement regarding eprotirome. Karo Bio will grant Alkem rights to commercialize eprotirome in India and certain other markets in Asia-Pacific and Africa. Karo Bio is entitled to royalty on Alkem's future sales of eprotirome.
Additional information available to subscribers only: